Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | ABCB1 | P08183 | 9/20 | 0.59 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | ABCC1 | P33527 | 3/20 | 0.58 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3059182 | 0.84 | KDM4E (0.64) | KDM4ETDP1GAAMAPTRAB9A | |
| SCHEMBL3054653 | 0.84 | KDM4E (0.62) | KDM4ETDP1MAPTABCB1ALDH1A1 | |
| SCHEMBL5131462 | 0.83 | KDM4E (0.71) | KDM4ETDP1REV1GAAMAPT | |
| SCHEMBL16061513 | 0.83 | L3MBTL1 (0.63) | KDM4EAKR1C3KMT2AALDH1A1CYP2D6 | |
| SCHEMBL5129280 | 0.82 | REV1 (0.66) | KDM4ETDP1REV1GAAMAPT | |
| SCHEMBL3050446 | 0.81 | KDM4E (0.51) | KDM4ETDP1REV1GAAMAPT | |
| SCHEMBL3052643 | 0.80 | KDM4E (0.53) | KDM4ETDP1REV1GAAMAPT | |
| SCHEMBL5130886 | 0.80 | REV1 (0.67) | KDM4ETDP1REV1GAAMAPT | |
| SCHEMBL3049297 | 0.80 | KDM4E (0.52) | KDM4ETDP1GAAMAPTRAB9A | |
| SCHEMBL5128393 | 0.79 | REV1 (0.69) | KDM4ETDP1REV1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180125811-A1 | 9,10-Alpha,Alpha-OH-Taxane Analogs and Methods for Production Thereof | TAPESTRY PHARMACEUTICALS, INC. | 2018-05-10 | — | — | US | disclosed |
| US-9820962-B2 | 9, 10-α, α-oh-taxane analogs and methods for production thereof | TAPESTRY PHARMACEUTICALS, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-9820962-B2 | 9, 10-α, α-oh-taxane analogs and methods for production thereof | TAPESTRY PHARMACEUTICALS, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20160331718-A1 | 9, 10-ALPHA, ALPHA-OH-TAXANE ANALOGS AND METHOD FOR PRODUCTION THEREOF | TAPESTRY PHARMACEUTICALS, INC. | 2016-11-17 | — | — | US | disclosed |
| US-20160331718-A1 | 9, 10-ALPHA, ALPHA-OH-TAXANE ANALOGS AND METHOD FOR PRODUCTION THEREOF | TAPESTRY PHARMACEUTICALS, INC. | 2016-11-17 | — | — | US | disclosed |
| US-9402824-B2 | 9,10-α, α-OH-taxane analogs and methods for production thereof | TAPESTRY PHARMACEUTICALS, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-9402824-B2 | 9,10-α, α-OH-taxane analogs and methods for production thereof | TAPESTRY PHARMACEUTICALS, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-20150133536-A1 | 9, 10-Alpha, Alpha-OH-Taxane Analogs and Methods for Production Thereof | TAPESTRY PHARMACEUTICALS, INC. (US) | 2015-05-14 | — | — | US | disclosed |
| US-20150133536-A1 | 9, 10-Alpha, Alpha-OH-Taxane Analogs and Methods for Production Thereof | TAPESTRY PHARMACEUTICALS, INC. (US) | 2015-05-14 | — | — | US | disclosed |
| US-8962870-B2 | 9, 10-α, α-OH-taxane analogs and methods for production thereof | TAPESTRY PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962870-B2 | 9, 10-α, α-OH-taxane analogs and methods for production thereof | TAPESTRY PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20120077871-A1 | 9, 10-Alpha, Alpha-OH-Taxane Analogs and Methods for Production Thereof | TAPESTRY PHARMACEUTICALS, INC. (US) | 2012-03-29 | — | — | US | disclosed |
| US-7879904-B2 | 9, 10-α,α-OH-taxane analogs and methods for production thereof | TAPESTRY PHARMACEUTICALS, INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20100324128-A1 | 9, 10-Alpha, Alpha-OH-Taxane Analogs and Methods for Production Thereof | TAPESTRY PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | US | disclosed |
| US-7745650-B2 | alpha stereochemistry at the C-9 and C-10 OH positions offers excellent inhibition of cell growth against MDR sensitive cancer cell lines; starting materials are Paclitaxel and Docetaxel; increased biological activity; side effect reduction; solubility; better therapeutic profile; anticancer | TAPESTRY PHARMACEUTICALS, INC (US) | 2010-06-29 | — | — | US | disclosed |
| EP-1664033-B1 | 9,10-ALPHA,ALPHA-OH-TAXANE ANALOGS AND METHODS FOR PRODUCTION THE REOF | TAPESTRY PHARMACEUTICALS INC (US) | 2007-11-07 | — | — | EP | disclosed |
| EP-1810968-A2 | 9, 10-a, a-OH-texane analogs and methods for production thereof | Tapestry Pharmaceuticals, Inc. (US) | 2007-07-25 | — | — | EP | disclosed |
| EP-1785416-A2 | 9, 10-alpha, alpha-OH-Taxane Analogs and methods for production thereof | Tapestry Pharmaceuticals, Inc. (US) | 2007-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324128-A1 | 9, 10-Alpha, Alpha-OH-Taxane Analogs and Methods for Production Thereof | ADCY9, TECR, AKR1C3 | KDM4E 4736/4885TDP1 2323/4885REV1 1402/4885 |
| US-20120077871-A1 | 9, 10-Alpha, Alpha-OH-Taxane Analogs and Methods for Production Thereof | TECR, ADCY9, AKR1C3 | KDM4E 4743/4885TDP1 2434/4885REV1 1485/4885 |
| US-20150133536-A1 | 9, 10-Alpha, Alpha-OH-Taxane Analogs and Methods for Production Thereof | TECR, ADCY9, AKR1C3 | KDM4E 4743/4885TDP1 2434/4885REV1 1485/4885 |
| US-20180125811-A1 | 9,10-Alpha,Alpha-OH-Taxane Analogs and Methods for Production Thereof | TECR, ADCY9, AKR1C3 | KDM4E 4743/4885TDP1 2434/4885REV1 1485/4885 |
| US-20160331718-A1 | 9, 10-ALPHA, ALPHA-OH-TAXANE ANALOGS AND METHOD FOR PRODUCTION THEREOF | TECR, ADCY9, AKR1C3 | KDM4E 4767/4885TDP1 2565/4885REV1 1558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.